

1 **Imbalance of Serum estrogen and** 2 **progesterone concentrations in puberty age** 3 **girls suffering from sickle cell anemia in tribal** 4 **population**

5 6 **Abstract**

7 About 7% of the world's population is carriers of some form of haemoglobin
8 disorder. There are about 270 million carriers of sickle cell anemia and/or
9 thalassemia. The level of ovarian steroids alters in girls suffering from sickle cell
10 anemia which causes complications such as hypogonadism which includes
11 amenorrhea or delayed menarche etc. by determining the level of these hormones in
12 sickle cell patients we can avoid many complications associated with the SCD thus
13 present study will help in prognosis of the disease in tribal individuals. There is no
14 significant difference between mean age of menarche in sickle cell trait (AS) and
15 normal individuals (AA), supporting the fact that the sickle cell trait lead an normal
16 life and seldom require treatment for their genetic condition.

17
18 Key words: - Puberty age, SCD, estrogen, sex-hormones, tribes.

19 **INTRODUCTION**

20 The sickle cell disease is a widespread genetic disorder characterized by red blood
21 cells assuming an abnormal, rigid, sickle shape that results in a risk of serious
22 complications. It occurs in high frequency in many tropical countries of the
23 world[1]. The sickling occurs due to a mutation in the haemoglobin gene.
24 Homozygosity of the gene, contributed by both the parent, result in to sickle cell
25 anaemia, whereas person with one recessive gene are called carrier or trait shows
26 asymptomatic sickle cell anemia[2]. Sickled haemoglobin polymerizes under deoxy
27 condition and therefore obstructs small blood vessels. While the carrier leads a
28 normal life, the diseased person suffers from various complications such as
29 anaemia, frequent infection, fever, hand-foot syndrome, stroke, acute chest pain,
30 vasoocclusive crisis, splenomegaly, renal failure, leg ulcers, hypogonadism etc[3].

31 In India, sickle cell gene is mainly restricted to tribal and scheduled caste
32 population. In our country, tribals with sickle gene are mainly concentrated in
33 Madhya Pradesh, Orissa, Chhattisgarh, Jharkhand, Gujarat, Andhra Pradesh etc[4].
34 Hypogonadism is one of the most prevalent endocrinopathies in subjects with SCD.
35 Delayed onset of puberty is a frequent finding in girls and boys with
36 SCD. Menarche is delayed by a mean interval of 2-3 years. A case control study
37 performed by Soliman *et. al.* found that two-thirds of girls with SCD have delayed
38 breast development (mean age of thelarche at 13.5 years), and the mean age of
39 spontaneous menarche is 15.6 years . Reasons for decreased growth are multi-
40 factorial with contributions from abnormal endocrine function. Estradiol is a steroid
41 hormone (molecular weight of 272.3 daltons), which are secreted principally by
42 ovarian follicles and also by adrenals, corpus luteum and placenta and in males by
43 testes. Estrogenic hormones are secreted at varying rates during the menstrual cycle
44 throughout period of ovarian activity[5,6,7]. Progesterone is a steroid hormone,
45 which plays an important role in the preparation and maintenance of pregnancy. It
46 is synthesized from cholesterol via pregnenolone then rapidly metabolized
47 to pregnenediol primarily in the liver. The ovary and placenta are major sites of
48 production but small amount is also produced by adrenal cortex in both men and
49 women. Circulating progesterone levels, which are characteristically low during
50 follicular phase and sharply increase during luteal phase of menstrual
51 cycle, reaching a maximum approximately 5 to 10 days after midcycle LH
52 peak[8]. The level of these ovarian steroids alters in girls suffering from sickle cell
53 anemia which causes complications such as hypogonadism which includes
54 amenorrhea or delayed menarche etc. by determining the level of these hormones in
55 sickle cell patients we can avoid many complications associated with the SCD thus
56 present study will help in prognosis of the disease[9,10]. Therefore the present
57 proposed research aimed to compare estradiol and progesterone level of sickle cell
58 patients (SS) as well as trait (AS) patients with normal individuals (AA)

59 MATERIALS AND METHODS

60 Materials:

61 All chemicals procured by standard analytical and preparative grade.

62 Study Population-

63 Blood samples were collected from subjects and volunteers (sickle cell patients) of
64 age between four and above years at the department of biochemistry centre for
65 genetic disease and molecular biology of Pt.J.N.M. Medical College and associated
66 Dr. B.R.A.M. hospital Raipur (C.G.).for this study control and study group was
67 taken from paediatrics and medicine O.P.D. of Dr. B.R.A.M. hospital and sickle
68 cell O.P.D. of Pt. J.N.M. medical college Raipur. Patient's samples were identified
69 after counselling and genotyping to determine their genotype group and some
70 already known sickle cell patients that attended the clinics and sickle cell centers
71 for routine medical check. No patients had any severe infection nor were on any
72 sort of medication. The volunteers were maintained as per norms of center ethics
73 committee on human research (CECHR) and local ethics committee
74

75 **Selection of cases:**

76 **Control group:** Control group consist of 50 normal puberty age girls and had no
77 clinical evidence of any sickle cell disease or other disorder.
78

79 **Study group :** Study group consist of 80 patients of puberty age girls attending
80 O.P.D. or admitted in medical college hospital Raipur suffering from sickle cell
81 disease out of 80 patients 30 were sickle cell disease (SS) and rest 50 were sickle
82 cell traits (AS).
83

84 **Biochemical tests**

86 **Collection of sample:**

87 All possible aseptic technique is used to collect the sample of blood 2 ml. In
88 sterile, dry, plain vial after which the blood is centrifuged for 15-20 minutes at
89 3000 rpm and supernatant (serum) is used for level of estradiol and
90 progesterone estimation.
91
92

93 **Solubility test:**

94 Deoxygenated Sickle cell haemoglobin has an abnormally low solubility. A fibrous
95 precipitate is formed when a concentrated solution of sickle cell haemoglobins
96 deoxygenated (This precipitate deforms red cells and gives them their sickle shape.
97 The rate of fibre formation is proportional to about the tenth power of the effective
98 concentration of deoxyhemoglobin S. Thus, fibre formation is a highly concerted
99 reaction) HbS is deoxygenated form and is insoluble in phosphate buffer (giving

100 turbidity to the solution) while other haemoglobins are completely soluble (giving
101 clear solution)[11].

102

103 One ml of phosphate buffer reagent was taken in a glass tube and a small quantity
104 of sodium dithionite was added to it and was mixed well to dissolve. A small drop
105 of washed red cells was added and was mixed well to produce light pinkish violet
106 colour. The test was read after 3 to 5 min. It was read as positive, if the turbidity
107 impaired the visibility of dark, bold lines on a white paper held against bright
108 source of light at one inch distance. Negative test was indicated by visible li

109 **Hb Electrophoresis:**

110

111 Each of the major haemoglobin types has an electrical charge of a different degree,
112 so the most useful method for separating and measuring normal and abnormal
113 haemoglobins is electrophoresis. This process involves subjecting haemoglobin
114 components from dissolved red blood cells to an electrical field. The components
115 then move away from each other at different rates, and when separated, form a
116 series of distinctly pigmented bands. The bands are then compared with the other
117 samples on the same membrane strip called as control[12]. Combination of
118 electrophoresis technique with solubility test is a golden standard for detecting
119 sickle cell haemoglobin in carrier and sufferer state. It is very cost effective.

120


121 **ELISA (Enzyme linked immunosorbent assay):**

122 Serum estradiol and progesterone level is estimated by using enzyme linked
123 immunosorbent assay (ELISA)[13,14].

124 **Competitive enzyme immunoassay:**

125 The interaction is illustrated by the followed equation:

126



128

129 A simultaneous reaction between the biotin attached to the antibody and the
130 streptavidin immobilized on the microwell occurs. This effects the separation of the
131 antibody bound fraction after decantation or aspiration.

132



134

135 The enzyme activity in the antibody bound fraction is inversely proportional to the
136 native antigen concentration. By utilizing several different serum references of
137 known antigen concentration, a dose response curve can be generated from which
138 the antigen concentration of an unknown can be ascertained.

139

140 **Statistical Analysis:** The result and observation recorded in this study was done by
141 using statistical model ANOVA (Analysis of Variance) and SEM. All data
142 analyzing withy use of SPSS statistical software version -11[15]

143

144 **Results& discussion**

145 Sickle cell disease (SCD) is an autosomal, recessive hemoglobinopathy
146 characterized by haemolytic anaemia, intermittent occlusion of small vessels
147 leading to acute and chronic tissue ischemia, and organ dysfunction. The result of
148 the clinical study start with sickle cell solubility test is a simple method that
149 detects the presence of sickle haemoglobin; of the 130 samples tested 80 samples
150 were found to be positive..But the solubility test does not distinguish between sickle
151 cell trait and sickle cell disorders. Positive samples are subjected to electrophoresis.
152 Each of the major haemoglobin types has an electrical charge of a different degree,
153 so the most useful method for separating and measuring normal and abnormal
154 haemoglobins is electrophoresis. Combination of electrophoretic technique with
155 solubility test is a golden standard for detecting sickle cell haemoglobin in carrier
156 and sufferer state. The mean age of menarche were estimated in sickle cell disease
157 (SS) girls, in sickle cell trait (AS) girls and control individuals (AS) .and mean age
158 of menarche of study group were compared with control group.The general
159 retardation of sexual development in girls with homozygous sickle cell (SS) disease
160 has been widely recognised since early descriptions [16] [17]. Menarche was
161 delayed by a mean interval of 1.7 years in Washington DC [18], and by 2.3–3.0
162 years in different studies in Jamaica [19-21]. Body weight and age were the best
163 predictors of menarche in the Cooperative Study of Sickle Cell Disease in the USA,
164 [22], A study in Jamaica identified fetal haemoglobin, and with less certainty,
165 height and social class as the best predictors [23].In present study Mean age of
166 menarche was found to be 13 years in normal individuals (AA), 13.08 years in

167 sickle cell trait (AS) and 15 years in sickle cell disease individual (SS). Mean age at
168 menarche is delayed by 2 years in SS diseased individuals as compared with normal
169 individuals.

170 The hormonal (estradiol and progesterone) level in sickle cell patients (In puberty
171 age girls). In this study the correlation of hormonal (estradiol and progesterone)
172 level with delayed menarche in girls with sickle cell anaemia was done by the
173 detection of the level of estradiol and progesterone. Estradiol and progesterone are
174 ovarian steroid hormones secreted principally by ovary. Its levels have been found
175 to be markedly decreased in sickle cell anemia. A fall in estradiol and progesterone
176 level extensively studied and demonstrated in sickle cell anaemia. The study
177 involved hormonal level detection by using enzyme linked immunosorbent assay
178 (ELISA) which is a very sensitive technique for hormonal level detection in serum
179 and which helps in prediction for prognosis of many diseases like hypogonadism in
180 sickle cell anaemia. There was general retardation of sexual development in girls
181 with homozygous sickle cell (SS) disease. Menarche was delayed by a mean
182 interval of 1.7 years in Washington DC, and by 2.3–3.0 years in different studies in
183 Jamaica. Jamaica identified fetal haemoglobin, and with less certainty, height and
184 social class as the best predictors. of menarche in the Cooperative Study of Sickle
185 Cell Disease age of 13 years in AA controls [57]. The Hgb, hematocrit, and
186 hemoglobinF concentration were associated with weight, height, and BMI scores in
187 females but not in males. In contrast, Zamel *et al*(2007) reported that Hgb
188 concentration was associated with height and weight in prepubertal Jamaican
189 males, but not females [63]. The finding of this study is that the estradiol and
190 progesterone level were found to be markedly decreased in sickle cell disease
191 person (SS) as compared with sickle cell trait (AS) as well as with normal
192 individuals (AA). And Menarche was delayed by a mean interval of 2 years in
193 sickle cell disease (SS) as compared to normal individuals. But there is no
194 significant difference in mean age of menarche of sickle cell trait (AS) and normal
195 individuals (AA). A feasible approach for detection of hypogonadism in sickle cell
196 anaemia has been presented. This analysis has been conducted by using enzyme
197 linked immunosorbent assay (ELISA) a very sensitive method; it has been able to
198 give the result by using nano gram (ng) or pico gram (pg) quantity of the
199 sample. The statistical results of estradiol and progesterone level were found to be

200 significant i.e. ($p < 0.01$) .which shows that the result of this study is statistically
201 significant.

202 **Conclusion**

203 Manifestations of endocrine and nutritional abnormalities are more common than
204 once perceived in patients with SCD with and without evidence of iron overload.
205 The current gaps in medical knowledge afford opportunities for future research
206 investigating optimal approaches to the diagnosis, intervention, and prevention of
207 these hormonal and nutritional dyscrasias. The present study concluded that the
208 menarche was delayed by a mean interval of 2 years in sickle cell disease
209 individuals (SS) as compared to normal individuals. estradiol and progesterone
210 level were found to be markedly decreased in sickle cell disease person (SS) as
211 compared with sickle cell trait (AS) as well as with normal individuals (AA) .There
212 is no significant difference between mean age of menarche in sickle cell trait (AS)
213 and normal individuals (AA), supporting the fact that the sickle cell trait lead an
214 normal life and seldom require treatment for their genetic condition.

215 **Reference**

216 1. Serjeant GR and Serjeant BE. Sickle Cell Disease. New York. Oxford University
217 Press, 2001.

218 2.Bhatia HM and Rao VR. Genetic Atlas of the Indian Tribes. Published by
219 Institute of Immunohaematology, (ICMR), Bombay, India. 1987.

220 3.Shamsuddeen, U., Mukhtar, M. D. and Maimuna, A. S. Prevalence of Sickle Cell
221 Anaemia among patients attending Malam Aminu Kano Teaching Hospital
222 (A.K.T.H.), Kano Nigeria. Department of biological sciences, Bayero university,
223 Kango, Nigeria.

224

225 4. Zemel BS, Kawchak DA and Ohene-Frempong K. Effects of Delayed Pubertal
226 Development, Nutritional Status, and Disease Severity on Longitudinal Patterns of
227 Growth Failure in Children With Sickle Cell Disease. *Pediatric Research*. 61:607–
228 613, 2007.

229 5. Balgir RS Age at menarche and first conception in sickle cell hemoglobinopathy.
230 *Indian Pediatr* 31: 827–832, 1994.

- 231 6. Soliman AT. Growth and pubertal development in transfusion-dependent
232 children and adolescents with thalassaemia major and sickle cell disease: a
233 comparative study. *J Trop Pediatr* 45: 23–30, 1999.
- 234 7. Thomas PW. Height and weight reference curves for homozygous sickle cell
235 disease. *Arch Dis Child* 82: 204–208, 2000.
- 236 8. Chatterjee R and Katz M. Reversible hypogonadotropic hypogonadism in
237 sexually infantile male thalassaemic patients with transfusional iron overload. *Clin*
238 *Endocrinol (Oxf)* 53: 33–42, 2000.
- 239 9. El-Hazmi MA. Endocrine functions in sickle cell anaemia patients. *J Trop*
240 *Pediatr* 38: 307–313, 1991.
- 241 10. Barden EM. Body composition in children with sickle cell disease. *Am J Clin*
242 *Nutr* 76: 218–225, 2002.
- 243
- 244 11. Colah RB, Surve RR, Nadkarni AH, Gorakshakar AC, Phanasgaonkar SP,
245 Satoskar P, and Mohanty D. Prenatal diagnosis of sickle syndromes in India
246 dilemmas in counseling. *Prenat. Diag. Vol. 25*.pp345-349, 2005.
- 247
- 248
- 249 12. Martin, H. and Steinberg. Disorders of hemoglobin: genetics, pathophysiology,
250 and clinical management, *The molecular cellular and genetic basis of hemoglobin*
251 *disorders*.25-30, 2001.
- 252
- 253 13. Nagel RL, Fabry ME and Pagnier J. Hematologically and genetically distinct
254 forms of sickle cell anemia in Africa. The Senegal type and the Benin type. *N Engl*
255 *J Med* 312:880-4, 1985.
- 256
- 257 14. Thein SL, Lynch JR, Old JM and Weatherall DJ. Direct detection of
258 haemoglobin E with Mnl I. *J Med Genet*, 24: 110-112, 1987.
- 259 15. Woodson RF. Statistical methods for the analysis of Biomedical
260 data, Probability and Mathematical statistics. Wiley, Chichester. 1987;315 -318.
261

262 16. Winsor T and Burch GE. *Habitus of patients with active sickle cell anemia of*
263 *long duration. Arch Intern Med 76:47–53, 1945.*

264 17. Jiminez CT, Scott RB and Henry WL. Studies in sickle cell anemia. XXVI. The
265 effects of homozygous sickle cell disease on the onset of menarche, pregnancy,
266 fertility, pubescent changes, and body growth in Negro subjects. *Am J Dis Child*
267 *111:497–504, 1966.*

268 18. Alleyne SI, D'Hereux Rauseo R and Serjeant GR. Sexual development and
269 fertility of Jamaican female patients with homozygous sickle cell disease. *Arch*
270 *Intern Med 141:1295–1297, 1981.*

271 19. Ashcroft MT and Serjeant GR. Growth, morbidity, and mortality in a cohort of
272 Jamaican adolescents with homozygous sickle cell disease. *W Ind Med J 30:197–*
273 *201, 1981.*

274 20 Graham C, Maude GH and Serjeant GR. Delayed menarche in homozygous sickle
275 cell disease. *W Ind Med J 35:18–22, 1986.*

276 21. Platt OS, Rosenstock W and Espeland MA. *Influence of sickle*
277 *hemoglobinopathies on growth and development. N Engl J Med 311:7–12, 1984.*


278 22. Zemel BS, Kawchak DA and Ohene-Frempong K. Effects of Delayed Pubertal
279 Development, Nutritional Status, and Disease Severity on Longitudinal Patterns of
280 Growth Failure in Children With Sickle Cell Disease. *Pediatric Research. 61(5, Part*
281 *1):607–613, 2007.*

282 .

283 **Table No. 1: Shows the number of sickle cell Diseased, trait patient and control**
284 **with their percentage.**

Groups	No. of patients	Percentage (%)
Control group (AA)	50	39
Study group (AS)	50	38
Study group (SS)	30	23
Total	130	100

285



286

287 **Figure 1: shows percentage of Control and Study group.**

288 There are 130 individuals in which 50 were control group which consist of 39% of
 289 total, other 50 were study group (AS) which consist of 38% of total and remaining
 290 30 were study group (SS) which consist of 23% of total.

291

292 **Table No. 2: Shows mean age of menarche in control and study groups.**

293

Group	No. Of cases	Mean age of menarche (yrs.)	S.D.
Control group (AA)	50	13	0.3112
Study group(AS)	50	13.08	0.1852
Study group (SS)	30	15	0.252

294

295 Age of menarche in control and study group were summarised by using mean and
 296 standard deviation. Age of menarche in control group was found to be 13 yrs. 13.08
 297 yrs. In sickle cell trait patients (AS) and 15 yrs. In sickle cell diseased patients.

298

299

300

301

302

303 **Table No. 3: shows mean serum progesterone level in controls.**

304

Age groups (yrs.)	13-14	15-16	17-18	19
No.of cases	16	13	9	12
Serum progesterone level (ng/ml)	13.90	12.90	12.11	10.28

305

306 Mean serum progesterone level was 13.90 ng/ml in 13-14 years, 12.90 ng/ml in 15-
307 16 years, 12.11 ng/ml in 17-18 years and 10.28 ng/ml in 19 years age.

308

309 **Table No. 4: shows mean serum progesterone level in study group (AS)**

310

Age groups (yrs.)	13-14	15-16	17-18	19
No. of cases	23	8	14	5
Serum progesterone level (ng/ml)	20.63	17.31	29.92	32.43

311

312 Mean serum progesterone level was 20.63 ng/ml in 13-14 years, 17.31 ng/ml in 15-
313 16 years, 29.92 ng/ml in 17-18 years and 32.53 in 19 year's age.

314

315 **Table No. 5: Shows mean serum progesterone level in study group (SS)**

Age group (yrs.)	13-14	15-16	17-18	19
No. Of cases	0	13	13	6
Serum progesterone level (ng/ml)		1.22	0.245	0.217

316

317 Mean serum progesterone level was 1.22 ng/ml in 15-16 years, 0.245 ng/ml in 17-
318 18 years and 0.217 ng/ml in 19 years age.

319 **Table No. 6: Shows mean serum estradiol level in controls (AA)**

Age group (yrs.)	13-14	15-16	17-18	19
No. Of cases	16	13	9	12
Serum estradiol level (pg/ml)	47.51	50.52	53.74	48.69

320

321 Mean serum estradiol level was 47.51 pg/ml in 13-14 years, 50.52 pg/ml in 15-16
322 years, 53.74 pg/ml in 17-18 years and 48.69 pg/ml in 19 years age.

323

324 **Table No. 7: Shows mean serum estradiol level in study groups (AS)**

Age group (yrs.)	13-14	15-16	17-18	19
No. Of cases	23	8	14	5
Serum estradiol level (pg/ml)	35.11	33.92	42.27	32.87

325

326 Mean serum estradiol level was 35.11 pg/ml in 13-14 years, 33.92 pg/ml in 15-16
327 years, 42.27 pg/ml in 17-18 years and 32.87 pg/ml in 19 years age.

328

329 **Table No. 8: Shows mean serum Estradiol level in study groups (SS)**

Age group (yrs.)	13-14	15-16	17-18	19
No. Of cases	0	13	13	6
Serum estradiol level (pg/ml)		11.51	22.16	33.20

330

331 Mean serum estradiol level was 11.51 pg/ml in 15-16 years, 22.16 pg/ml in 17-18
332 years, 33.20 pg/ml in 19 years age.

333

334 **Table No. 9: Shows Serum progesterone level in control Vs study group.**

Group	No. Of cases	Serum progesterone level			
		Mean (ng/ml)	S.D.	P	Significance
Control group (AA)	50	28.9	2.178	<0.01	Significant
Study group (AS)	50	23.88	2.084		
Study group (SS)	30	0.66	1.579		

335

336 Above are Statistical results of serum progesterone level whose levels are ($p < 0.01$)
337 shown statistically significant.

338 **Table No. 10: shows serum estradiol level in control Vs. Study group**

Group	No. Of cases	Serum estradiol level			
		Mean (pg/ml)	S.D.	P	Significance
Control group (AA)	50	49.70	2.308	$P < 0.01$	Significant
Study group (AS)	50	37.49	1.940		
Study group (SS)	30	24.30	3.100		

339

340 Above are statistical results of serum estradiol level whose levels are ($p < 0.01$)
341 shown statistically significant.


342

343 **Table No.11: shows statistical data of serum estradiol and progesterone level.**

Hormones	No. Of cases	Mean	S.D.	F value	P	Significance
Estradiol	130	39.14 (pg/ml)	7.348	10.79	<0.01	Significant
Progesterone	130	12.52 (ng/ml)	5.359	20.71	<0.01	Significant


344

345 Above are statistical results of serum estradiol and serum progesterone level whose
 346 levels are ($p < 0.01$) which shows that the levels are statistically significant.
 347



348
 349 **Figure 2: Mean age of menarche in control Vs. Study group.**

350




351
 352
 353 **Figure 3: Mean Serum progesterone level in control vs. study group**

354

355

356

357



358

359

360

Figure 4: Mean Serum estradiol level in control Vs. study group